Miltenyi University: Bridging Binder Discovery And Automated CAR T Cell Manufacturing From CD19 To CLDN6

Solid tumors remain a difficult setting for CAR T therapy, and CLDN6 offers a target worth examining closely. The work traces a path from binder discovery and construct generation through to automated manufacturing, treating development and production as one connected problem rather than separate stages. It also considers how an established automated platform, the CliniMACS Prodigy, can ease technology transfer, support process consistency, and allow production to scale across future CAR T cell programs.

Explore how early design decisions and manufacturing strategy shape one another in a solid tumor program.